Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease ContinuumAndréa Lessa Benedet, Alyssa Stevensson, Natàlia Vilor‐Tejedor et al.|JAMA Neurology|2021Cited by 627
A multicentre validation study of the diagnostic value of plasma neurofilament lightNicholas J. Ashton, Oskar Hansson, Shorena Janelidze et al.|Nature Communications|2021Cited by 554
The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's diseaseJoel Simrén, Nicholas J. Ashton, Antoine Leuzy et al.|Alzheimer s & Dementia|2021Cited by 354
Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s diseaseMarta Milà‐Alomà, Kaj Blennow, Nicholas J. Ashton et al.|Nature Medicine|2022Cited by 349
Biomarker modeling of Alzheimer’s disease using PET-based Braak stagingJoseph Therriault, Pedro Rosa‐Neto, Tharick A. Pascoal et al.|Nature Aging|2022Cited by 300